GE Partners in Single-Use Biomanufacturing
GE Healthcare will install its proprietary FlexFactory manufacturing platform in a new facility in Hsinchu Industrial Park, Taiwan owned by United BioPharma (UBP), a Taipei City, Taiwan-headquartered biopharmaceutical company. The installation expands production capacity at the facility, which focuses on late-stage clinical and commercial production of therapeutic monoclonal antibodies (mAbs).
The Hsinchu facility will be dedicated to late-stage clinical and commercial production of biopharmaceuticals, including UB-421, a mAb in development for treating HIV. GE will also continue to work with UBP on establishing its contract development and manufacturing organization business. UBP and GE are partnered under GE’s Fast Trak collaboration, which includes Fast Trak centers that provide advanced laboratories, large-scale equipment, and process-related support for UBP’s research and development team.
GE Healthcare’s FlexFactory is a centrally automated, flexible biomanufacturing platform that allows manufacturers to establish biopharmaceutical manufacturing capacity within an existing building or as part of a new facility. FlexFactory is primarily comprised of single-use technologies and associated process hardware and is integrated with automation and control components.
Source: GE Healthcare